Wall Street brokerages expect Medidata Solutions Inc (NASDAQ:MDSO) to report earnings of $0.36 per share for the current quarter, according to Zacks Investment Research. Seven analysts have made estimates for Medidata Solutions’ earnings, with the lowest EPS estimate coming in at $0.32 and the highest estimate coming in at $0.39. Medidata Solutions posted earnings of $0.33 per share in the same quarter last year, which indicates a positive year over year growth rate of 9.1%. The company is scheduled to announce its next quarterly earnings report on Thursday, October 25th.
According to Zacks, analysts expect that Medidata Solutions will report full year earnings of $1.57 per share for the current financial year, with EPS estimates ranging from $1.50 to $1.65. For the next financial year, analysts forecast that the firm will report earnings of $1.94 per share, with EPS estimates ranging from $1.71 to $2.10. Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for Medidata Solutions.
Medidata Solutions (NASDAQ:MDSO) last issued its earnings results on Tuesday, July 24th. The company reported $0.43 EPS for the quarter, beating the Zacks’ consensus estimate of $0.39 by $0.04. Medidata Solutions had a return on equity of 11.37% and a net margin of 9.13%. The firm had revenue of $155.90 million for the quarter, compared to analyst estimates of $155.86 million. During the same quarter in the prior year, the firm earned $0.31 earnings per share. Medidata Solutions’s revenue for the quarter was up 14.6% on a year-over-year basis.
Several equities research analysts have commented on the company. ValuEngine upgraded Medidata Solutions from a “hold” rating to a “buy” rating in a research report on Friday, August 24th. BidaskClub upgraded Medidata Solutions from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 16th. Royal Bank of Canada set a $98.00 price objective on Medidata Solutions and gave the stock a “buy” rating in a research report on Tuesday, July 24th. Morgan Stanley set a $84.00 price objective on Medidata Solutions and gave the stock a “hold” rating in a research report on Wednesday, July 25th. Finally, Needham & Company LLC lowered Medidata Solutions from a “buy” rating to a “hold” rating in a research report on Wednesday, July 25th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $87.62.
In other news, CFO Rouven Bergmann sold 3,000 shares of the stock in a transaction that occurred on Thursday, July 19th. The stock was sold at an average price of $85.36, for a total transaction of $256,080.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Robert Taylor sold 5,000 shares of the stock in a transaction that occurred on Tuesday, July 31st. The shares were sold at an average price of $73.05, for a total value of $365,250.00. Following the transaction, the director now owns 44,036 shares in the company, valued at approximately $3,216,829.80. The disclosure for this sale can be found here. Insiders have sold a total of 32,788 shares of company stock worth $2,574,487 in the last quarter. Insiders own 4.70% of the company’s stock.
Several large investors have recently made changes to their positions in MDSO. Comerica Bank raised its stake in Medidata Solutions by 9.3% in the 1st quarter. Comerica Bank now owns 61,772 shares of the company’s stock valued at $4,537,000 after purchasing an additional 5,250 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. acquired a new position in Medidata Solutions in the 1st quarter valued at $26,769,000. Kornitzer Capital Management Inc. KS raised its stake in Medidata Solutions by 17.1% in the 1st quarter. Kornitzer Capital Management Inc. KS now owns 161,900 shares of the company’s stock valued at $10,169,000 after purchasing an additional 23,665 shares during the last quarter. American Century Companies Inc. raised its stake in Medidata Solutions by 0.3% in the 1st quarter. American Century Companies Inc. now owns 1,444,426 shares of the company’s stock valued at $90,724,000 after purchasing an additional 4,716 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA acquired a new position in Medidata Solutions in the 1st quarter valued at $14,028,000.
Medidata Solutions stock traded up $0.30 during mid-day trading on Friday, hitting $82.93. The company had a trading volume of 9,579 shares, compared to its average volume of 375,934. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.16. Medidata Solutions has a 12-month low of $59.60 and a 12-month high of $88.87. The firm has a market cap of $5.07 billion, a PE ratio of 97.45, a P/E/G ratio of 5.33 and a beta of 1.45.
About Medidata Solutions
Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development of new therapies. The company's platform solutions include data capture and management and trial planning and management.
See Also: Index Funds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.